Oppenheimer analyst Justin Kim downgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Outperform to Perform.
Cowen & Co. Maintains Outperform on NanoString Technologies, Lowers Price Target to $24
Cowen & Co. analyst Dan Brennan maintains NanoString Technologies (NASDAQ:NSTG) with a Outperform and lowers the price target from $31 to $24.